Skip to content
Axe Capital logo Axe Capital Trading News

Axe Capital Investments

Clear market notes built around the JSE, the rand, and what matters locally.

Axe Capital Trading News shares simple market takes on the stories moving South African shares, the rand, and a handful of major currency pairs.

Coverage focus:

1. JSE shares, South African companies, and the local knock-on effects of big market news.

2. The rand, interest rates, and a small group of forex pairs, with USD/ZAR at the centre.

3. Global stories only when they can actually change how a local investor might act.

Latest Finance Headlines

Could $5,000 in Ares Capital Generate $500 a Year in Passive Income?
2026-07-21 13:30 The Motley Fool Positive Axe Cap view: Selective

Ares Capital (ARCC) currently yields just over 10%, which would generate approximately $500 annually on a $5,000 investment. While the BDC has maintained a stable or growing dividend for over 16 consecutive years, recent concerns exist as core earnings fell short of the quarterly dividend in Q1. However, the company's realized gains, spillover income cushion, modest leverage, and stable interest rate environment suggest the dividend remains sustainable.

Axe note: ARCC’s strong dividend track record looks appealing despite recent earnings hiccups.

Could Investing in This Space Stock Make You a Millionaire?
2026-07-21 13:30 The Motley Fool Neutral Axe Cap view: Selective

Redwire is positioning itself as an infrastructure provider for space-based manufacturing, research, power, and commercial operations. The company's future depends on whether space becomes a true industrial economy. While the opportunity is significant, investors must carefully weigh both the potential and the substantial risks involved.

Axe note: Investing in space infrastructure stocks like Redwire is a high-risk, high-reward bet with uncertain timelines.

Novo Nordisk's Dividend Story Is Changing -- Here's What Investors Are Missing
2026-07-21 13:15 The Motley Fool Positive Axe Cap view: Selective

Novo Nordisk offers an attractive 3.5% dividend yield backed by a shifting business model focused on volume-driven growth in GLP-1 weight-loss drugs. Despite 2026 being a transition year with pricing pressures and generic competition, the company's strong pill formulation demand and solved supply issues position it well. The stock trades below five-year valuation averages, making it appealing for dividend investors seeking recurring income similar to its insulin business.

Axe note: Novo Nordisk’s growing GLP-1 drug volume could support a safe 3.5% dividend despite near-term hurdles.

Focus Areas

We keep the focus on JSE shares, the rand, and the currency moves that matter most to South African investors.

Market notes